Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a listed company controlled by Guangzhou Pharmaceutical Holdings Limited (A-share 600332, H-share 00874). Its main businesses include: (1) Research, development, manufacturing, and sales of Chinese and Western medicines, chemical active pharmaceutical ingredients (APIs), natural drugs, biopharmaceuticals, and chemical API intermediates; (2) Wholesale, retail, and import/export of Western medicines, Chinese medicines, and medical devices; (3) Research, development, production, and sales of health products in the large health industry; and (4) Investment in healthcare services, health management, wellness, elderly care, and other health-related industries. After years of meticulous development and rapid growth, the group has gradually formed four major business segments: "Large Pharmaceuticals," "Large Health," "Large Commerce," and "Large Healthcare," as well as three new business models: "E-commerce," "Capital Finance," and "Medical Devices." The group oversees 25 pharmaceutical manufacturing enterprises and institutions (including 3 branches, 19 holding subsidiaries, and 3 joint ventures), among which there are 12 time-honored Chinese pharmaceutical brands and 10 century-old enterprises. The group exclusively produces over 100 specifications of traditional Chinese medicine products (including holding subsidiaries and joint ventures).